WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Victoria Beckham reveals she stores her designer wardrobe in special heatMyanmar junta chief missing from public view after drone attack — Radio Free AsiaTrump to meet with senior Japanese official after court session Tuesday in hush money trialRichmond Mayor Stoney drops Virginia governor bid, he will run for lieutenant governor insteadThe UK government finally passes bill to send migrants to Rwanda. What took so long?Pregnant Draya Michele, 39, and NBA star boyfriend Jalen Green, 22, host cherryAboriginal spears taken by Captain Cook in 1770 are returned to Australia's Indigenous peopleThe UK government finally passes bill to send migrants to Rwanda. What took so long?Celine Dion reveals she wore a coat for 'nerveUnassuming New Jersey home hits the market for $400,000
1.7926s , 6496.4921875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,International Intrigue news portal